Current Report Filing (8-k)
01 March 2023 - 10:59PM
Edgar (US Regulatory)
0001710340
false
0001710340
2023-03-01
2023-03-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 1, 2023
Date
of Report (Date of earliest event reported)
ETON
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-38738 |
|
37-1858472 |
(State
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
21925
W. Field Parkway, Suite 235
Deer
Park, Illinois 60010-7208
(Address
of principal executive offices) (Zip code)
(847)
787-7361
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
ETON |
|
NASDAQ
Global Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item
5.02. |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
Effective
March 1, 2023, Eton Pharmaceuticals, Inc. (“Eton”
or the “Company”) has appointed David Krempa to the position of Chief Business Officer. Mr. Krempa previously was
employed by the Company in the Position of Senior Vice President, Business Development and Investor Relations.
In
connection with the appointment as Chief Business Officer, Mr. Krempa will receive an annual salary of $385,000 and is eligible for an
annual discretionary bonus as determined by the board of directors. Mr. Krempa also participates in the Company’s 2018 Equity
Incentive Plan along with other officers and employees of the Company. Mr. Krempa’s employment with the Company is “at will”
and his employment may be terminated by the Company at any time for any reason or for no reason. In the event Mr. Krempa’s employment
is terminated without “cause” or he terminates his employment for “good reason,” he will receive six months’
of his base salary as severance. Further, if such termination occurs within twelve months of a change in control of the Company, all
of Mr. Krempa’s unvested stock options shall immediately vest.
Mr.
Krempa has been employed full time by the Company since 2017. Prior to his appointment as Chief Business Officer, he served as Senior
Vice President, Business Development and Investor Relations since April 2021, Vice President, Business Development from March 2019 to
April 2021, and prior to that he served as Executive Director, Business Development since September 2017. Mr. Krempa received his B.S.
in Finance from DePaul University.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
March 1, 2023 |
By: |
/s/
James R. Gruber |
| |
|
James
R. Gruber |
| |
|
Chief
Financial Officer and Secretary |
| |
|
(Principal
Financial Officer) |
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Apr 2023 to Apr 2024
